Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Inebilizumab-cdon in Rheumatoid Arthritis: NCT06570798 Clinical Landscape Report 2026
16 October 2026
NCT06570798 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Budoprutug in Systemic Lupus Erythematosus: NCT06570434 Clinical Landscape Report 2026
16 October 2026
NCT06570434 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talquetamab in Extramedullary Disease in Multiple Myeloma: NCT06572605 Clinical Landscape Report 2026
16 October 2026
NCT06572605 clinical landscape for Extramedullary Disease in Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
GSK-4527363 in Systemic Lupus Erythematosus: NCT06576271 Clinical Landscape Report 2026
16 October 2026
NCT06576271 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD38/CS1 Chimeric Antigen Receptor T Cell(The Second Hospital of Shandong University) in Recurrent Multiple Myeloma: NCT06574958 Clinical Landscape Report 2026
16 October 2026
NCT06574958 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogenic Adipose Tissue Derived-MSCs(China Medical University Hospital) in Scleroderma: NCT06574581 Clinical Landscape Report 2026
16 October 2026
NCT06574581 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YKST02 in Multiple Myeloma: NCT06574568 Clinical Landscape Report 2026
16 October 2026
NCT06574568 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06577025 Clinical Landscape Report 2026
16 October 2026
NCT06577025 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Primary peritoneal carcinoma: NCT06580314 Clinical Landscape Report 2026
16 October 2026
NCT06580314 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Uveal Melanoma: NCT06581406 Clinical Landscape Report 2026
16 October 2026
NCT06581406 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Riluzole in Hodgkin's Lymphoma: NCT06580002 Clinical Landscape Report 2026
16 October 2026
NCT06580002 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AB-101 (Artiva) in Granulomatosis With Polyangiitis: NCT06581562 Clinical Landscape Report 2026
16 October 2026
NCT06581562 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…